Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling
Abstract
Docetaxel plays an indispensable role in the management of advanced prostate cancer. However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence, a second agent that could increase the initial efficacy of docetaxel and maintain tolerability at biologically effective doses may improve outcomes for patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1569
Entities
People
- Anindita Das
- Benjamin A Teply
- Jawed A. Siddiqui
- Kaustubh Datta
- Kavita Mallya
- Lei Xi
- Parthasarathy Seshacharyulu
- Prakash Kshirsagar
- Raghupathy Vengoji
- Rakesh C Kukreja
- Ridwan Islam
- Sakthivel Muniyan
- Sanchita Rauth
- Seema Parte
- Surinder K Batra
- Sushanta Halder
Organizations
- National Institutes of Health
- United States Department of Defense
- University of Nebraska Medical Center
- Virginia Commonwealth University